New combo shot aims to tame type 1 diabetes
NCT ID NCT07087795
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new weekly injection called NNC0194-0499, alone or with another drug (semaglutide), in 96 adults with type 1 diabetes. The goal is to see if it improves blood sugar levels compared to placebo. All participants continue their usual insulin. The study lasts about 36 weeks and focuses on safety and blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0194-0499 (a new weekly injection) and semaglutide (a diabetes drug)
What this could lead to
If it works, this could point toward a new combination treatment to help people with type 1 diabetes manage their blood sugar levels more effectively.
What could go wrong
This is an early Phase 1 trial with only 96 people, so it is not yet proven to be safe or effective. The results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany